Table 2.
RR and study power in LRFS, DRFS, DFS, and OS in BCS
| Study | pCR, n (%) | LR | DR | DFS | OS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall event/event | RR | Power | Overall event/event | RR | Power | Overall event/event | RR | Power | Overall event/event | RR | Power | ||
| Caudle 2012 [19] | 124 (20.8) | 37/3 | 0.34 | 0.605 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Bonadonna 2002 [20] | 7 (3.3) | 8/0 | 1.52 | 0.106 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Fastner 2014 [17] | 15 (14.0) | 6/0 | 0.45 | 0.247 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Noh 2014 [25]a | 102 (39.2) | 13/2 | 0.28 | 0.476 | 18/1 | 0.09 | 0.911 | 55/3 | 0.09 | 1 | 9/0 | 0.08 | 0.751 |
| Shen 2004 [16]a | 4 (12.1) | 5/0 | 0.55 | 0.195 | 9/0 | 0.32 | 0.345 | NA | NA | NA | NA | NA | NA |
| Cho 2013 [22] | 38 (30.6) | 6/0 | 0.17 | 0.482 | 16/1 | 0.15 | 0.723 | 21/1 | 0.11 | 0.897 | 15/4 | 0.82 | 0.066 |
| Jimbo 2014 [21] | 63 (32.5) | 5/2 | 1.39 | 0.065 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Yamazaki 2015 [26]a | 56 (25.8) | 14/6 | 2.16 | 0.276 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Rouzier 2001 [10] | 28 (10.9) | 41/2 | 0.42 | 0.328 | 71/4 | 0.49 | 0.441 | NA | NA | NA | NA | NA | NA |
| Mclntosh 2003 [18] | 18 (40.9) | 1/0 | 0.47 | 0.138 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Beriwal 2006 [24]a | 37 (24.2) | 21/4 | 0.74 | 0.095 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| total | 492 (22.4) | 157/19 | 0.59 | 0.933 | 114/6 | 0.27 | 1 | 76/4 | 0.09 | 1 | 24/4 | 0.36 | 0.589 |
Abbreviation: RR risk ratio, LR local recurrence, DR distance recurrence, DFS disease-free survival, OS overall survival, pCR pathology complete response, NA not available
aMeans the definition of pCR was the absence of invasive component in the primary breast tumor, irrespective of pathological axillary node status